Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Catherine M Skefos x
Clear All Modify Search
Catherine M Skefos The University of Texas MD Anderson Cancer Center, Clinical Cancer Genetics Program, Houston, Texas, USA

Search for other papers by Catherine M Skefos in
Google Scholar
PubMed
Close
,
Pamela L Brock The Ohio State University College of Medicine, Division of Human Genetics, Comprehensive Cancer Center, Columbus, Ohio, USA

Search for other papers by Pamela L Brock in
Google Scholar
PubMed
Close
,
Erica Blouch Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA

Search for other papers by Erica Blouch in
Google Scholar
PubMed
Close
, and
Samantha E Greenberg Department of Health Care Sciences, UT Southwestern Medical Center, Dallas, Texas, USA

Search for other papers by Samantha E Greenberg in
Google Scholar
PubMed
Close

This commentary explores the complexities faced by clinicians when encountering a secondary SDHA pathogenic variant (PV) in patients without a personal or family history of SDHA-related tumors. The increasing use of germline multi-gene panel testing has led to a rise in such secondary findings, necessitating a nuanced approach to counseling, surveillance, and decision-making. We aim to discuss the current data surrounding the penetrance of SDHA PVs, the spectrum of screening guidelines, recommendations for educating individuals and families about their secondary findings, and the need for future research to optimize care for these individuals. Practical recommendations for clinicians dealing with patients with secondary SDHA findings include acknowledging the limitations of existing guidelines, fostering shared decision-making, and considering specialist referrals. Overall, the evolving landscape of SDHA penetrance data warrants ongoing reassessment of surveillance approaches.

Open access